EP4127209A4 - SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER - Google Patents

SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER Download PDF

Info

Publication number
EP4127209A4
EP4127209A4 EP21775064.5A EP21775064A EP4127209A4 EP 4127209 A4 EP4127209 A4 EP 4127209A4 EP 21775064 A EP21775064 A EP 21775064A EP 4127209 A4 EP4127209 A4 EP 4127209A4
Authority
EP
European Patent Office
Prior art keywords
chd1l
oncogenic
small molecule
colorectal cancer
activity against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21775064.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4127209A2 (en
Inventor
Daniel V. Labarbera
Joshua M. ABBOTT
Qiong ZHOU
Hector ESQUER
Brett Joseph PRIGARO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
University of Colorado Colorado Springs
University of Colorado Denver
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
University of Colorado Denver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System, University of Colorado Colorado Springs, University of Colorado Denver filed Critical University of Colorado System
Publication of EP4127209A2 publication Critical patent/EP4127209A2/en
Publication of EP4127209A4 publication Critical patent/EP4127209A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21775064.5A 2020-03-24 2021-03-24 SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER Pending EP4127209A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994259P 2020-03-24 2020-03-24
US202163139394P 2021-01-20 2021-01-20
PCT/US2021/023981 WO2021195279A2 (en) 2020-03-24 2021-03-24 Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer

Publications (2)

Publication Number Publication Date
EP4127209A2 EP4127209A2 (en) 2023-02-08
EP4127209A4 true EP4127209A4 (en) 2024-07-24

Family

ID=77892666

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21775064.5A Pending EP4127209A4 (en) 2020-03-24 2021-03-24 SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER

Country Status (6)

Country Link
EP (1) EP4127209A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023520330A (cg-RX-API-DMAC7.html)
CN (1) CN115667553A (cg-RX-API-DMAC7.html)
AU (1) AU2021244209A1 (cg-RX-API-DMAC7.html)
CA (1) CA3172987A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021195279A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024525158A (ja) * 2021-06-17 2024-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア E3リガーゼ阻害剤及びその使用方法
AU2022354855A1 (en) * 2021-09-30 2024-04-18 The Regents Of The University Of Colorado, A Body Corporate Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectral cancer
CN114457007B (zh) * 2022-02-28 2024-05-28 合肥燃音生物科技有限公司 一种基于微孔板的均一的单类器官模型及其制备方法
CN119365198A (zh) * 2022-05-02 2025-01-24 艾斯巴赫生物有限公司 ALC1抑制剂的用途和与PARPi的协同作用
CN115290774B (zh) * 2022-07-21 2023-07-21 重庆医科大学 尿苷二磷酸葡萄糖醛酸在制备用于检测肝癌试剂中的应用
WO2024211314A2 (en) * 2023-04-03 2024-10-10 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of chd1l and uses thereof
CN122070131A (zh) 2023-10-25 2026-05-19 艾斯巴赫生物有限公司 在同源重组缺陷型(hrd)癌症的治疗中使用的作为alc1抑制剂的吡啶并噻吩并嘧啶衍生物
AU2024366320A1 (en) * 2023-10-25 2026-04-16 Eisbach Bio Gmbh Alc1 inhibitors for use in treating cancer by potentiating the effects of several classes of approved cancer drugs
WO2025093706A1 (en) * 2023-10-31 2025-05-08 Eisbach Bio Gmbh Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan
WO2025129032A1 (en) * 2023-12-15 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Chd1l inhibitors for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109761909A (zh) * 2019-01-25 2019-05-17 中国药科大学 N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211603A1 (en) * 2004-08-18 2006-09-21 Vicuron Pharmaceuticals Inc. Ramoplanin derivatives possessing antibacterial activity
SG10201500124VA (en) * 2010-01-08 2015-03-30 Agency Science Tech & Res Methods and Compositions for Treating Cancer
WO2012166722A1 (en) * 2011-06-03 2012-12-06 The General Hospital Corporation Treating colorectal, pancreatic, and lung cancer
MX355354B (es) * 2012-08-23 2018-04-17 Virostatics Srl Derivados aminopirimidinicos 4,6-disustituidos novedosos.
US20160138114A1 (en) * 2013-06-19 2016-05-19 The Regents Of The University Of California Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer
CN108976172B (zh) * 2017-05-31 2021-12-07 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109761909A (zh) * 2019-01-25 2019-05-17 中国药科大学 N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途

Also Published As

Publication number Publication date
CA3172987A1 (en) 2021-09-30
EP4127209A2 (en) 2023-02-08
AU2021244209A1 (en) 2022-11-03
WO2021195279A3 (en) 2021-11-11
JP2023520330A (ja) 2023-05-17
CN115667553A (zh) 2023-01-31
WO2021195279A2 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
EP3843711A4 (en) METHODS OF CANCER TREATMENT WITH SMALL MOLECULE PD-L1 INHIBITORS
AU2021376500A9 (en) Application of isoquinoline compound in tumor treatment
EP4216801A4 (en) HYDRATION TRACKING USING BASELINE CALIBRATION
EP4284802A4 (en) SMALL MOLECULE INHIBITORS OF SALT-INDUCIBLE KINASES
AU2021348463A1 (en) Indoline compounds and derivatives as egfr inhibitors
WO2010002779A3 (en) Naphthyridininones as aurora kinase inhibitors
EP4291565A4 (en) SYNTHETIC CINCHONA ALKALOIDS AGAINST CANCER
AU2023411337A1 (en) Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
EP4281063A4 (en) OXABICYCLOHEPTANE FOR THE TREATMENT OF SMALL CELL LUNG CANCER
EP4408411A4 (en) SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER
CA3257264A1 (en) CANCER GROWTH INHIBITION METHODS
AU2022231043A1 (en) Chaperonin-containing tcp-1 inhibitors for the treatment of cancer
AU2024328571A1 (en) Treatment of solid cancer with lasofoxifene
CA3302440A1 (en) Treatment of solid cancer with lasofoxifene
CA3303178A1 (en) Treatment of non small cell lung cancer with alectinib
HK40086336A (en) Small molecule inhibitors of slc15a4 with antiinflammatory activity
AU2022903574A0 (en) Colorectal cancer risk assessment
HK40117011A (en) Lasofoxifene treatment of aromatase-resistant er+ cancer
HK40116999A (en) Use of amivantamab to treat colorectal cancer
AU2020902437A0 (en) Determining cancer responsiveness to treatment
AU2020900934A0 (en) Determining cancer responsiveness to treatment
HK40111633A (zh) 作为hpk1抑制剂用於治疗癌症的经取代的吡嗪-2-甲酰胺
CA3269203A1 (en) Compounds with anti-tumor activity against kras mutated tumors
HK40102279A (en) Urea derivatives which can be used to treat cancer
HK40118676A (en) Treatment of cancer with an fgfr kinase inhibitor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230505

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: PRIGARO, BRETT JOSEPH

Inventor name: ESQUER, HECTOR

Inventor name: ZHOU, QIONG

Inventor name: ABBOTT, JOSHUA M.

Inventor name: LABARBERA, DANIEL V.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12Q0001680000

Ipc: C07D0239480000

A4 Supplementary search report drawn up and despatched

Effective date: 20240625

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20240619BHEP

Ipc: C07D 487/04 20060101ALI20240619BHEP

Ipc: C07D 471/04 20060101ALI20240619BHEP

Ipc: C07D 409/12 20060101ALI20240619BHEP

Ipc: C07D 403/12 20060101ALI20240619BHEP

Ipc: C07D 239/48 20060101AFI20240619BHEP